Oppenheimer raised the firm’s price target on Perspective Therapeutics to $19 from $2 to reflect consolidation of shares after the stock began trading on a 10-for-1 reverse split basis. The firm keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics CEO buys $117.4K in common stock
- Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
- Perspective Therapeutics announces inclusion in the Russell 3000 Index
- Perspective Therapeutics announces 1-for-10 reverse stock split
- Perspective Therapeutics Announces 1-for-10 Reverse Stock Split